Epigenetic drugs in the treatment of skeletal muscle atrophy

Dulbecco Telethon Institute (DTI) at Fondazione Santa Lucia/EBRI, Rome, Italy.
Current Opinion in Clinical Nutrition and Metabolic Care (Impact Factor: 3.99). 06/2008; 11(3):233-41. DOI: 10.1097/MCO.0b013e3282fa1810
Source: PubMed


A dynamic network of anabolic and catabolic pathways regulates skeletal muscle mass in adult organisms. Muscle atrophy is the detrimental outcome of an imbalance of this network. The purpose of this review is to provide a critical evaluation of different forms of muscle atrophy from a mechanistic and therapeutic point of view.
The identification and molecular characterization of distinct pathways implicated in the pathogenesis of muscle atrophy have revealed potential targets for therapeutic interventions. However, an effective application of these therapies requires a better understanding of the relative contribution of these pathways to the development of muscle atrophy in distinct pathological conditions.
We propose that the decline in anabolic signals ('passive atrophy') and activation of catabolic pathways ('active atrophy') contribute differently to the pathogenesis of muscle atrophy associated with distinct diseases or unfavorable conditions. Interestingly, these pathways might converge on common transcriptional effectors, suggesting that an optimal intervention should be directed to targets at the chromatin level. We provide the rationale for the use of epigenetic drugs such as deacetylase inhibitors, which target multiple signaling pathways implicated in the pathogenesis of muscle atrophy.

Download full-text


Available from: Pier Lorenzo Puri
    • "2011 ; Benny Klimek et al . 2010 ; Guasconi and Puri 2008 ; Wagner et al . 2008 ) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human longevity is a complex trait and increasingly we understand that both genes and lifestyle interact in the longevity phenotype. Non-genetic factors, including diet, physical activity, health habits, and psychosocial factors contribute approximately 50 % of the variability in human lifespan with another 25 % explained by genetic differences. Family clusters of nonagenarian and centenarian siblings, who show both exceptional age-span and health-span, are likely to have inherited facilitatory gene groups, but also have nine decades of life experiences and behaviours which have interacted with their genetic profiles. Identification of their shared genes is just one small step in the link from genes to their physical and psychological profiles. Behavioural genomics is beginning to demonstrate links to biological mechanisms through regulation of gene expression, which directs the proteome and influences the personal phenotype. Epigenetics has been considered the missing link between nature and nurture. Although there is much that remains to be discovered, this article will discuss some of genetic and environmental factors which appear important in good quality longevity and link known epigenetic mechanisms to themes identified by nonagenarians themselves related to their longevity. Here we suggest that exceptional 90-year old siblings have adopted a range of behaviours and life-styles which have contributed to their ageing-well-phenotype and which link with important public health messages.
    No preview · Article · Jul 2015 · Biogerontology
  • Source
    • "Dystrophic muscle, however, may ultimately signal these progenitors to become fibroadipocytes that promote fibrosis and fat deposition rather than muscle regeneration [141, 142]. These signals, which determine the fate of the fibroadipocytes, are driven by epigenetic marks – specifically, chromatin modifications such as histone acetylation – that regulate gene expression [143, 144]. Even in genetically-identical cells, gene expression may be regulated differently via epigenetic mechanisms, including methylation of DNA and acetylation of histone proteins [145-147]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Duchenne muscular dystrophy (DMD) is a devastating disease that dramatically decreases the lifespan and abilities of affected young people. The primary molecular cause of the disease is the absence of functional dystrophin protein, which is critical to proper muscle function. Those with DMD vary in disease presentation and dystrophin mutation; the same causal mutation may be associated with drastically different levels of disease severity. Also contributing to this variation are the influences of additional modifying genes and/or changes in functional elements governing such modifiers. This genetic heterogeneity complicates the efficacy of treatment methods and to date medical interventions are limited to treating symptoms. Animal models of DMD have been instrumental in teasing out the intricacies of DMD disease and hold great promise for advancing knowledge of its variable presentation and treatment. This review addresses the utility of comparative genomics in elucidating the complex background behind phenotypic variation in a canine model of DMD, Golden Retriever muscular dystrophy (GRMD). This knowledge can be exploited in the development of improved, more personalized treatments for DMD patients, such as therapies that can be tailor-matched to the disease course and genomic background of individual patients.
    Full-text · Article · Aug 2013 · Current Genomics
  • Source
    • "As discussed above, the acetylation balance of chromatin regulates cell determination and cell fate suggesting that epigenetic drugs could prove useful for the treatment of muscle diseases, neurodegenerative disorders, and cancer. In the last decade, we provided several evidences in vitro and in vivo indicating that DIs could be a valid tool for pharmacological interventions in muscle dystrophies [19, 42, 88–90]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The balance between protein acetylation and deacetylation controls several physiological and pathological cellular processes, and the enzymes involved in the maintenance of this equilibrium-acetyltransferases (HATs) and deacetylases (HDACs)-have been widely studied. Presently, the evidences obtained in this field suggest that the dynamic acetylation equilibrium is mostly maintained through the physical and functional interplay between HAT and HDAC activities. This model overcomes the classical vision in which the epigenetic marks of acetylation have only an activating function whereas deacetylation marks have a repressing activity. Given the existence of several players involved in the preservation of this equilibrium, the identification of these complex networks of interacting proteins will likely foster our understanding of how cells regulate intracellular processes and respond to the extracellular environment and will offer the rationale for new therapeutic approaches based on epigenetic drugs in human diseases.
    Full-text · Article · Jan 2011 · BioMed Research International
Show more